Claman on Call: FBN’s Liz Claman with an after-hours web exclusive on the markets, oil prices, and a federal investigation into Bill Ackman ’s Herbalife controversy.
Pershing Square founder and CEO Bill Ackman on what makes him tick, learning from mistakes and best career advice.
WSJ’s David Benoit on activist investors and Bill Ackman ’s investing strategy.
Pershing Square founder and CEO Bill Ackman on the 2015 Harbor Investment Conference and why activist investors are important for corporate America.
FBN’s Deidre Bolton talks to Pershing Square Capital Founder and CEO Bill Ackman about the role of the activist investor.
Herbalife CFO John DeSimone reacts to Pershing Square Capital Management CEO Bill Ackman ’s latest attacks.
Maureen Farrell of The Wall Street Journal on Pershing Square Capital Management CEO Bill Ackman ’s comments on Herbalife.
FBN contributor Bob Rice delves into Pershing Square Capital Management CEO Bill Ackman ’s disclosure of details into Herbalife’s investigation.
Wall Street Journal reporter David Benoit and FOX Business contributor Bob Rice on Allergan looking to potential acquisitions to fend off activist investor Bill Ackman .
Billionaire activist investor William Ackman said today that the way he accumulated his stake in Botox-maker Allergan (NYSE:AGN) was above the board and did not viol...
Hedge fund manager Jeffrey Ubben, whose firm ValueAct sits on the board of Valeant Pharmaceuticals, said on Tuesday that the hedge fund will not seek reelection on t...
In an unusual partnership with activist investor William Ackman, Valeant Pharmaceuticals International Inc. proposed to buy Botox-maker Allergan Inc. on Tuesday. Und...
Valeant Pharmaceuticals (NYSE:VRX) on Tuesday unveiled a cash-and-stock buyout offer for Botox-maker Allergan (NYSE:AGN). The deal, which was initially announced Mon...
FBN’s Charlie Gasparino discusses Pershing Square CEO Bill Ackman ’s latest comments on Herbalife and the federal probe of alleged market manipulation.
Pershing Square CEO Bill Ackman discusses his outlook for the probe, why he reinvested in Valiant and how he thinks hedge funds impact the average investor.
Pershing Square CEO Bill Ackman argues Herbalife has lost the ability to predict the future of its business.
Pershing Square CEO Bill Ackman discusses the investigations into alleged market manipulation and a pyramid scheme at Herbalife.
Pershing Square CEO Bill Ackman argues there is no future for Herbalife as a legal company.
Pershing Square Capital Founder and CEO Bill Ackman on the role of activist investors, biggest mistakes and investing strategies.
FBN’s Deirdre Bolton with details on her interview with activist investor Bill Ackman .